pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
15d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
15d
Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
fiercebiotech
15d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
15d
China biotech Minghui does thyroid eye disease deal for $110M upfront
endpoints
15d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
16d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
16d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
16d
‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts
stat
16d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
16d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
17d
FDA peptide policy risks undermining drug development and patient safety
biospace
17d
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
biospace
17d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
17d
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
stat
17d
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
biopharma dive
17d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
17d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
20d
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
fda press
20d
Vitality Works Inc. Recalls 365 Whole Foods Market Ashwagandha Capsules Sold Nationwide Due to Potential Salmonella Contamination
fda recalls
20d
This week in charts: ESMO’s winners and losers
biopharma dive
20d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
20d
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
biospace
20d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
20d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
20d
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
biospace
20d
Once undruggable, the Wnt/B-catenin pathway shows increasing promise
biospace
20d
Opinion: How Congress can fix expert advisory committees
stat
20d
Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M
endpoints
20d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
20d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
← prev
page 4 of 34
next →